Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ICLR's Cash to Debt is ranked higher than
90% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.07 vs. ICLR: No Debt )
ICLR' s 10-Year Cash to Debt Range
Min: 0.85   Max: No Debt
Current: No Debt

Equity to Asset 0.65
ICLR's Equity to Asset is ranked higher than
71% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ICLR: 0.65 )
ICLR' s 10-Year Equity to Asset Range
Min: 0.53   Max: 0.77
Current: 0.65

0.53
0.77
Interest Coverage 94.07
ICLR's Interest Coverage is ranked higher than
64% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. ICLR: 94.07 )
ICLR' s 10-Year Interest Coverage Range
Min: 17.93   Max: 9999.99
Current: 94.07

17.93
9999.99
F-Score: 8
Z-Score: 5.79
M-Score: -2.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.79
ICLR's Operating margin (%) is ranked higher than
77% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. ICLR: 6.79 )
ICLR' s 10-Year Operating margin (%) Range
Min: 2.27   Max: 12.11
Current: 6.79

2.27
12.11
Net-margin (%) 5.76
ICLR's Net-margin (%) is ranked higher than
78% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ICLR: 5.76 )
ICLR' s 10-Year Net-margin (%) Range
Min: 1.76   Max: 13.44
Current: 5.76

1.76
13.44
ROE (%) 11.29
ICLR's ROE (%) is ranked higher than
80% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. ICLR: 11.29 )
ICLR' s 10-Year ROE (%) Range
Min: 3.36   Max: 17.12
Current: 11.29

3.36
17.12
ROA (%) 7.13
ICLR's ROA (%) is ranked higher than
82% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. ICLR: 7.13 )
ICLR' s 10-Year ROA (%) Range
Min: 2.23   Max: 10.38
Current: 7.13

2.23
10.38
ROC (Joel Greenblatt) (%) 63.02
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. ICLR: 63.02 )
ICLR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.88   Max: 63.02
Current: 63.02

11.88
63.02
Revenue Growth (%) 11.20
ICLR's Revenue Growth (%) is ranked higher than
82% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. ICLR: 11.20 )
ICLR' s 10-Year Revenue Growth (%) Range
Min: -14.6   Max: 54.5
Current: 11.2

-14.6
54.5
EBITDA Growth (%) 8.70
ICLR's EBITDA Growth (%) is ranked higher than
75% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. ICLR: 8.70 )
ICLR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 36.6
Current: 8.7

0
36.6
EPS Growth (%) 4.60
ICLR's EPS Growth (%) is ranked higher than
73% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ICLR: 4.60 )
ICLR' s 10-Year EPS Growth (%) Range
Min: -34.2   Max: 54.4
Current: 4.6

-34.2
54.4
» ICLR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ICLR Guru Trades in Q2 2013

Paul Tudor Jones 150,000 sh (New)
Steven Cohen 60,275 sh (+184.18%)
Jim Simons 283,160 sh (+82.14%)
Ron Baron 1,022,800 sh (+24.31%)
Jean-Marie Eveillard 12,000 sh (unchged)
Meridian Funds 308,000 sh (unchged)
Stanley Druckenmiller Sold Out
RS Investment Management 430,460 sh (-3.22%)
Chuck Royce 267,348 sh (-30.81%)
» More
Q3 2013

ICLR Guru Trades in Q3 2013

Jim Simons 495,160 sh (+74.87%)
Ron Baron 1,280,000 sh (+25.15%)
RS Investment Management 470,360 sh (+9.27%)
Jean-Marie Eveillard 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 210,200 sh (-21.38%)
Steven Cohen 9,031 sh (-85.02%)
» More
Q4 2013

ICLR Guru Trades in Q4 2013

Paul Tudor Jones 200,000 sh (New)
Steven Cohen 219,406 sh (+2329.48%)
Jim Simons 830,860 sh (+67.8%)
Ron Baron 1,430,000 sh (+11.72%)
RS Investment Management 500,960 sh (+6.51%)
Jean-Marie Eveillard 12,000 sh (unchged)
Chuck Royce 210,200 sh (unchged)
» More
Q1 2014

ICLR Guru Trades in Q1 2014

Caxton Associates 15,000 sh (New)
Ron Baron 1,430,000 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
Chuck Royce 210,200 sh (unchged)
RS Investment Management Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 195,389 sh (-10.95%)
Jim Simons 712,260 sh (-14.27%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2013-09-30 Add 25.15%0.05%$36.24 - $40.67 $ 47.4923%1280000
Ron Baron 2013-06-30 Add 24.31%0.04%$29.2 - $36.22 $ 47.4944%1022800
Meridian Funds 2013-03-31 Reduce -33.19%0.17%$27.25 - $32.91 $ 47.4959%308000
Ron Baron 2013-03-31 New Buy0.15%$27.25 - $32.91 $ 47.4959%822800
Meridian Funds 2012-12-31 Reduce -28.22%0.16%$23.46 - $28.54 $ 47.4980%461000
Meridian Funds 2012-06-30 Add 24.87%0.1%$20.51 - $23.23 $ 47.49118%642200
Meridian Funds 2012-03-31 Add 25.16%0.06%$17.06 - $22.01 $ 47.49150%514300
Jean-Marie Eveillard 2011-09-30 Add 36.36%$16.5 - $25.21 $ 47.49130%15000
Meridian Funds 2011-06-30 New Buy0.24%$21.18 - $25.92 $ 47.4998%351000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Icon PLC

Baron Funds Comments on ICON PLC - Jun 10, 2013

Other purchases in the quarter include ICON plc (ICLR), which is a CRO (Contract Research Organization) providing outsourced drug research to the pharmaceutical industry. We observed from our investment in Covance that the industry is turning, so we purchased a stake in ICON to increase the Fund's exposure to the trend.

From Baron Funds’ first quarter 2013 commentary.
Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 24.90
ICLR's P/E(ttm) is ranked higher than
84% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 24.90 )
ICLR' s 10-Year P/E(ttm) Range
Min: 4.37   Max: 78.79
Current: 24.9

4.37
78.79
P/B 3.10
ICLR's P/B is ranked higher than
77% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.83 vs. ICLR: 3.10 )
ICLR' s 10-Year P/B Range
Min: 0.46   Max: 5.55
Current: 3.1

0.46
5.55
P/S 1.70
ICLR's P/S is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. ICLR: 1.70 )
ICLR' s 10-Year P/S Range
Min: 0.58   Max: 2.14
Current: 1.7

0.58
2.14
PFCF 18.20
ICLR's PFCF is ranked higher than
91% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 18.20 )
ICLR' s 10-Year PFCF Range
Min: 5.14   Max: 600.13
Current: 18.2

5.14
600.13
EV-to-EBIT 18.29
ICLR's EV-to-EBIT is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 18.29 )
ICLR' s 10-Year EV-to-EBIT Range
Min: 1.4   Max: 50.5
Current: 18.29

1.4
50.5
PEG 15.50
ICLR's PEG is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 15.50 )
ICLR' s 10-Year PEG Range
Min: 0.08   Max: 11.49
Current: 15.5

0.08
11.49
Shiller P/E 35.60
ICLR's Shiller P/E is ranked higher than
93% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 35.60 )
ICLR' s 10-Year Shiller P/E Range
Min: 6.42   Max: 36.47
Current: 35.6

6.42
36.47
Current Ratio 1.81
ICLR's Current Ratio is ranked higher than
56% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. ICLR: 1.81 )
ICLR' s 10-Year Current Ratio Range
Min: 1.48   Max: 3.61
Current: 1.81

1.48
3.61
Quick Ratio 1.81
ICLR's Quick Ratio is ranked higher than
59% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. ICLR: 1.81 )
ICLR' s 10-Year Quick Ratio Range
Min: 1.48   Max: 3.61
Current: 1.81

1.48
3.61

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 14.75
ICLR's Price/Net Current Asset Value is ranked higher than
82% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 14.75 )
ICLR' s 10-Year Price/Net Current Asset Value Range
Min: 1.84   Max: 107.9
Current: 14.75

1.84
107.9
Price/Tangible Book 5.13
ICLR's Price/Tangible Book is ranked higher than
75% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.75 vs. ICLR: 5.13 )
ICLR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 7.03
Current: 5.13

0.64
7.03
Price/DCF (Projected) 1.40
ICLR's Price/DCF (Projected) is ranked higher than
93% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 1.40 )
ICLR' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 6.85
Current: 1.4

0.52
6.85
Price/Median PS Value 1.41
ICLR's Price/Median PS Value is ranked higher than
70% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ICLR: 1.41 )
ICLR' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 1.58
Current: 1.41

0.46
1.58
Price/Graham Number 2.37
ICLR's Price/Graham Number is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ICLR: 2.37 )
ICLR' s 10-Year Price/Graham Number Range
Min: 0.41   Max: 3.59
Current: 2.37

0.41
3.59
Earnings Yield (Greenblatt) 5.50
ICLR's Earnings Yield (Greenblatt) is ranked higher than
67% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ICLR: 5.50 )
ICLR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 71.7
Current: 5.5

2
71.7
Forward Rate of Return (Yacktman) 1.45
ICLR's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.81 vs. ICLR: 1.45 )
ICLR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.2   Max: 62
Current: 1.45

-16.2
62

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0NBW.country
Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It develops, manages, and analyses programs that support all stages of clinical development process - from compound selection to Phase I-IV clinical studies. The Company provides its customers clinical research services which include: clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services.
» More Articles for NAS:ICLR

Headlines

Articles On GuruFocus.com
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 
ICON publie ses orientations financières pour l’année 2009 et les mises à jour des orientations Jan 09 2009 
Resumen: ICON presenta previsiones financieras para 2009 y actualiza las de 2008 Jan 09 2009 
Samenvatting: ICON publiceert cijfers voor 2009 en werkt cijfers 2008 bij Jan 09 2009 
ICON veröffentlicht Ergebniserwartung für 2009 und aktualisiert Erwartung für 2008 (NASDAQ:ICLR) Jan 09 2009 
ICON Issues Financial Guidance for 2009 and Updates Guidance for 2008 (NASDAQ:ICLR) (ISIN:IE00057112 Jan 09 2009 
Riassunto: ICON rende noti gli orientamenti finanziari per il 2009 e un aggiornamento degli orientam Jan 09 2009 

More From Other Websites
ICON and the University of Cambridge Collaborate to Deliver Educational Programme on Pricing &... Jul 22 2014
Irish Stocks Come To Prominence As Taxes Stay Low Jul 14 2014
Jazz, Novo Among Medicals Showing Healthy Action Jul 07 2014
UBS New Stocks to Buy for Growth at a Reasonable Price Jun 17 2014
Updated Research Report on Healthways May 30 2014
CROs rally after AstraZeneca rejects final bid from Pfizer May 19 2014
Intrexon (XON) Jumps: Stock Moves 12.8% Higher May 15 2014
RadNet Touches New 52-Week High May 12 2014
Icon Plc - Investing In Biotechs With Reduced Risk May 09 2014
ICON plc to host analyst day May 09 2014
Why ICON Public (ICLR) Could Beat Earnings Estimates Again May 09 2014
ICON to Webcast Analyst Day Meeting May 09 2014
ICON Completes Acquisition of Aptiv Solutions May 08 2014
Can ICON Public Limited Company (ICLR) Stock Continue to Grow Earnings? May 07 2014
Charles River, PAREXEL lower after peers combine May 01 2014
ICON Public Limited Management Discusses Q1 2014 Results - Earnings Call Transcript Apr 30 2014
ICON PLC Earnings Call scheduled for 9:00 am ET today Apr 30 2014
Q1 2014 ICON PLC Earnings Release - Time Not Supplied Apr 30 2014
ICON Announces Appointment of Dr. Hugh Brady to Board of Directors Apr 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide